Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lyncean Technologies Inc. Sells Compact Light Source to Munich Biomedical-Imaging Research Center

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
Palo Alto-based Lyncean Technologies, Inc., announced its first sale of a Compact Light Source, a miniature synchrotron X-ray source employing state-of-the-art laser-beam and electron-beam technology.

A Lyncean "Compact Light Source" (CLS) was purchased by researchers from the newly-formed Center for Advanced Laser Applications (CALA) in Germany, a joint project of the Ludwig Maximilians University of Munich (LMU) and the Technical University Munich (TUM). The device will be fully built and tested in Lyncean's facility in Palo Alto, Calif. and delivered to Munich in early 2014.

"Today is a milestone for us," said Ronald Ruth, Lyncean's founder and Chairman of the Board. "We feel we have an innovative tool, especially as X-rays are playing a growing role in areas like structural biology, medical science, nanotech and fuel cell research. We've been fortunate to have had so much support developing the technology, but putting a CLS in the hands of scientists has always been the ultimate goal."

With its first sale to a team of researchers, Lyncean expects a growing demand by scientists and students at the forefront of biomedical X-ray imaging research. Prof. Franz Pfeiffer, Chair for Biomedical Physics at TUM, leads a group of X-ray scientists pioneering new imaging techniques that reveal striking details in soft tissue that have been difficult to detect using conventional methods. He's eager to see the new X-ray source put to use.

"The field of X-ray imaging is evolving rapidly, and with this novel source, we are adding a powerful tool to our facility," Dr. Pfeiffer said. "I expect having our own CLS here in Munich will significantly boost the research projects in our excellence cluster Munich-Centre for Advanced Photonics (MAP)."

Lyncean has been collaborating with Dr. Pfeiffer's group informally since 2007, when an impromptu visit one afternoon led to an experiment and later publication that was featured on the cover of the Journal of Synchrotron Radiation in January 2009, [doi:10.1107/S090904950803464X]. Subsequent experiments using the CLS prototype operating at Lyncean have produced a variety of joint publications, primarily with a medical emphasis, highlighting the machine's ability to improve tumor detection and early diagnosis of lung disease (a study that was just published in the Proceedings of the National Academy of Sciences [doi: 10.1073/pnas.1206684109]).

"Because the CLS is a new breed of X-ray source, with unique properties, we work with X-ray scientists to understand their applications," Dr. Ruth said. "The TUM collaboration is a good example of how we can successfully adapt our source for a particular application, in this case biomedical imaging."

The US National Institutes of Health provided funding for CLS development in order to help address the growing demand of life-science users who rely on synchrotrons for structural biology research. In addition to the CLS, Lyncean has also developed X-ray applications such as protein crystallography and power diffraction using focused beams from special X-ray optics. Researchers, though, use a wide variety of experimental techniques when applying synchrotron radiation to their own problems. The CLS, like a large synchrotron facility, is designed to perform a breadth of X-ray applications spanning fields from biology and chemistry to nanotechnology and materials science.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!